These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 19652878

  • 1. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V, Pannell R.
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [Abstract] [Full Text] [Related]

  • 2. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
    Pannell R, Kung W, Gurewich V.
    J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
    [Abstract] [Full Text] [Related]

  • 3. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.
    Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A.
    PLoS One; 2011 May; 6(7):e21999. PubMed ID: 21779364
    [Abstract] [Full Text] [Related]

  • 4. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.
    Pannell R, Li S, Gurewich V.
    PLoS One; 2015 May; 10(3):e0122018. PubMed ID: 25811605
    [Abstract] [Full Text] [Related]

  • 5. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
    Liu JN, Liu JX, Liu Bf BF, Sun Z, Zuo JL, Zhang Px PX, Zhang J, Chen Yh YH, Gurewich V.
    Circ Res; 2002 Apr 19; 90(7):757-63. PubMed ID: 11964367
    [Abstract] [Full Text] [Related]

  • 6. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
    Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF.
    J Thromb Haemost; 2006 Jul 19; 4(7):1559-65. PubMed ID: 16839354
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH, Diamond SL.
    J Clin Invest; 1995 Jun 19; 95(6):2483-90. PubMed ID: 7769094
    [Abstract] [Full Text] [Related]

  • 9. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R, Li S, Gurewich V.
    J Thromb Thrombolysis; 2017 Aug 19; 44(2):210-215. PubMed ID: 28600623
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 14. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D.
    Blood; 1992 Jan 15; 79(2):417-29. PubMed ID: 1730087
    [Abstract] [Full Text] [Related]

  • 15. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA, Huang TC, Keyt BA, Alevriadou BR.
    Ann Biomed Eng; 1998 Jan 15; 26(4):712-24. PubMed ID: 9662163
    [Abstract] [Full Text] [Related]

  • 16. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N, Iwamoto M, Abiko Y.
    Thromb Res; 1987 Aug 15; 47(4):459-68. PubMed ID: 2821651
    [Abstract] [Full Text] [Related]

  • 17. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M, Lijnen HR, Keber D, Collen D.
    Thromb Haemost; 1989 Dec 29; 62(4):1083-7. PubMed ID: 2515603
    [Abstract] [Full Text] [Related]

  • 18. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH, Diamond SL.
    Thromb Haemost; 1995 Aug 29; 74(2):711-7. PubMed ID: 8585011
    [Abstract] [Full Text] [Related]

  • 19. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
    Aisina R, Mukhametova L, Varfolomeyev S.
    Biochim Biophys Acta; 2016 Apr 29; 1860(4):629-35. PubMed ID: 26723174
    [Abstract] [Full Text] [Related]

  • 20. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.